XML 21 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Composition of Certain Balance Sheet Items
 3 Months Ended
Mar. 31, 2023
Balance Sheet Related Disclosures [Abstract]  
Composition of Certain Balance Sheet Items Composition of Certain Balance Sheet Items
Inventory
March 31,
2023		December 31,
2022
 (in thousands)
Work in progress$8,514 $7,827 
Finished goods8,051 9,204 
Total inventory16,565 17,031 
Less strategic inventory classified as non-current(10,156)(10,931)
Total inventory classified as current$6,409 $6,100 
Because we rely on a single manufacturer to produce Korlym’s active pharmaceutical ingredient (“API”), we have purchased and hold significant quantities of API, included in work in progress inventory. We classify inventory we do not expect to sell within 12 months of the balance sheet date as “Strategic inventory,” a long-term asset.
Property and equipment, net
March 31,
2023		December 31,
2022
(in thousands)
Furniture and equipment$1,235 $1,235 
Software1,508 1,508 
Leasehold improvements1,597 1,597 
Total property and equipment4,340 4,340 
Less accumulated depreciation and amortization(3,879)(3,707)
Property and equipment, net$461 $633 
Accrued and other liabilities
March 31,
2023		December 31,
2022
 (in thousands)
Government rebates$15,478 $11,098 
Income taxes payable8,589 89 
Accrued compensation7,806 15,511 
Legal fees3,421 2,673 
Professional fees1,498 211 
Accrued selling and marketing costs1,081 434 
Other1,220 783 
Total accrued and other liabilities$39,093 $30,799 
Other assets
As of March 31, 2023 and December 31, 2022, other assets included $4.6 million and $4.9 million of deposits for clinical trials, respectively.